Literature DB >> 12072206

Establishment and characterization of human metastatic hepatocellular carcinoma cell line.

Jian Ming Wen1, Jie Fu Huang, Liang Hu, Wei Sheng Wang, Meng Zhang, Jonathan S T Sham, Jian Min Xu, Wei Fen Zeng, Dan Xie, Li Jian Liang, Xin Yuan Guan.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with a poor prognosis. Recently, we established a HCC cell line from a metastatic HCC tumor. GTG banding analysis was performed and the karyotype showed that this metastatic HCC cell line is a hypertriploid (71-78 chromosomes) with a large marker chromosome containing a long homogeneously staining region (hsr). Comparative genomic hybridization was applied to characterize the chromosomal alterations in this metastatic HCC cell line. The results showed that the hsr was composed of amplified DNA sequences from 11q13. Further characterization of the hsr may lead to the isolation of the putative amplified oncogene at 11q13.

Entities:  

Mesh:

Year:  2002        PMID: 12072206     DOI: 10.1016/s0165-4608(01)00636-7

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98.

Authors:  Chao-Yang Lou; Ying-Ming Feng; Ai-Rong Qian; Yu Li; Hao Tang; Peng Shang; Zhi-Nan Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

Review 2.  Experimental models of hepatocellular carcinoma: developments and evolution.

Authors:  Long Wu; Zhao-You Tang; Yan Li
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-28       Impact factor: 4.553

3.  Characterization of genetic rearrangements in esophageal squamous carcinoma cell lines by a combination of M-FISH and array-CGH: further confirmation of some split genomic regions in primary tumors.

Authors:  Jia-Jie Hao; Zhi-Zhou Shi; Zhi-Xin Zhao; Yu Zhang; Ting Gong; Chun-Xiang Li; Ting Zhan; Yan Cai; Jin-Tang Dong; Song-Bin Fu; Qi-Min Zhan; Ming-Rong Wang
Journal:  BMC Cancer       Date:  2012-08-24       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.